Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders and inflammatory diseases. It has several innovative small molecule and biological drug candidates at different stages of clinical development. IGC became an owner in Biotie when Biotie acquired Synosia Therapeutics, an IGC investment, in 2008.
- Sector: Healthcare
- Status: Public (HELSINKI: BTH1V)
- Geographic Market: Europe
- Investment Year: 2010
- Investment Team: Richard Treffner
Visit the company’s website.